Order Article Reprints

Zheng B, Lou F, He Y, Fu M, Huang X, Tan W, Chen Q, Xie X, Hu T, Xiao L. Deeper Analysis to Identify the True Benefit of ICIs Immunotherapy in First-Line Treatment for Non-HER2-Positive/HER2-Negative Advanced or Metastatic Advanced or Metastatic Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJC). Cancers. 2025; 17(4):657. https://doi.org/10.3390/cancers17040657

Zheng, Bowen, Fanzhuoran Lou, Yuting He, Miao Fu, Xintian Huang, Weijuan Tan, Quan Chen, Xiaowen Xie, Tianhui Hu, and Li Xiao. 2025. "Deeper Analysis to Identify the True Benefit of ICIs Immunotherapy in First-Line Treatment for Non-HER2-Positive/HER2-Negative Advanced or Metastatic Advanced or Metastatic Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJC)" Cancers 17, no. 4: 657. https://doi.org/10.3390/cancers17040657

Zheng, B., Lou, F., He, Y., Fu, M., Huang, X., Tan, W., Chen, Q., Xie, X., Hu, T., & Xiao, L. (2025). Deeper Analysis to Identify the True Benefit of ICIs Immunotherapy in First-Line Treatment for Non-HER2-Positive/HER2-Negative Advanced or Metastatic Advanced or Metastatic Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJC). Cancers, 17(4), 657. https://doi.org/10.3390/cancers17040657